XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Equity (Unaudited) - USD ($)
$ in Thousands
Total
Additional Paid-in Capital
Accumulated Deficit
Accumulated other comprehensive income
Noncontrolling interests
Treasury Stock
Series A
Common Stock
Series B
Common Stock
Balance at Jul. 31, 2022 $ 97,206 $ 262,023 $ (165,457) $ 3,704 $ (3,309)   $ 8 $ 237
Balance (in Shares) at Jul. 31, 2022             787,163 23,687,964
Net income (loss) 1,493   1,592 (99)  
Stock-based compensation 1,180 1,180    
Stock-based compensation (in Shares)            
Shares withheld for payroll taxes (6) (6)  
Shares withheld for payroll taxes (in Shares)             (2,928)
Unrealized gain on available-for-sale securities 103 103  
Foreign currency translation adjustment (10) (10)  
Balance at Oct. 31, 2022 99,966 263,197 (163,865) 3,797 (3,408)   $ 8 $ 237
Balance (in Shares) at Oct. 31, 2022             787,163 23,685,036
Balance at Jul. 31, 2023 96,629 264,010 (167,333) 3,372 (3,664)   $ 8 $ 236
Balance (in Shares) at Jul. 31, 2023             787,163 23,490,527
Net income (loss) (3,760) (3,638) (122)  
Stock-based compensation 649 647   $ 2
Stock-based compensation (in Shares)             246,408
Shares withheld for payroll taxes (39) (39)  
Shares withheld for payroll taxes (in Shares)             (17,920)
Unrealized gain on available-for-sale securities 207 207  
Sale of Rafael Medical Devices membership units 925 869 56  
Purchases of treasury stock (79)   $ (79)
Purchases of treasury stock (in Shares)           50,700 (50,700)
Dissolution of Levco 56 19 37  
Foreign currency translation adjustment (76) (76)  
Balance at Oct. 31, 2023 $ 94,512 $ 265,487 $ (170,971) $ 3,522 $ (3,693) $ (79) $ 8 $ 238
Balance (in Shares) at Oct. 31, 2023           50,700 787,163 23,668,315